21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
- 1 December 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (25), 2336-2347
- https://doi.org/10.1056/nejmoa2108873
Abstract
The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary lymph-node–negative breast cancer. In women with positive lymph-node disease, the role of the recurrence score with respect to predicting a benefit of adjuvant chemotherapy is unclear.Keywords
Funding Information
- National Cancer Institute (U10CA180888, U10CA180819, U10CA180820, U10CA180)
- Susan G. Komen for the Cure Research Program
- The Hope Foundation for Cancer Research
- Breast Cancer Research Foundation
- Genomic Health, Inc.
This publication has 28 references indexed in Scilit:
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast CancerThe New England Journal of Medicine, 2010
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP SystemJournal of Clinical Oncology, 2007
- Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004